Condition: Acute Ischemic Stroke · Sponsor: NoNO Inc.
ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
This description comes directly from the study's public registry record.
Michael Tymianski, MD PhD · 416-583-1687 · mtymianski@nonoinc.ca
Always discuss trial participation with your own doctor first.
| University of Calgary - Foothills Medical Centre | Calgary, Alberta, Canada | Recruiting |
| University of Alberta Hospital | Edmonton, Alberta, Canada | Recruiting |
| Vancouver General Hospital | Vancouver, British Columbia, Canada | Recruiting |
| University of Manitoba | Winnipeg, Manitoba, Canada | Recruiting |
| Hamilton General Hospital | Hamilton, Ontario, Canada | Recruiting |
| Ottawa Hospital Research Institute | Ottawa, Ontario, Canada | Recruiting |
| Sunnybrook Health Sciences Centre | Toronto, Ontario, Canada | Recruiting |
| Unity Health Toronto, St. Michael's Hospital | Toronto, Ontario, Canada | Recruiting |
| Royal University Hospital | Saskatoon, Saskatchewan, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06403267